Oxytetracycline

Summary

Oxytetracycline (CHEMBL1517) is an approved small molecule (ATC J01AA06); indicated across 5 conditions including bacterial infectious disease and eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01AA06 (+5 more)
• Indications: 5 conditions
• Clinical trials: 2
• Chemistry: 460.4 Da · C22H24N2O9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1517
Name	Oxytetracycline
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	54675779
ChEBI	CHEBI:133011
ATC	J01AA06, D06AA03, A01AB25, S01AA04, G01AA07, J01AA56
Molecular formula	C22H24N2O9
Molecular weight	460.4
InChIKey	OWFJMIVZYSDULZ-PXOLEDIWSA-N

SMILES: C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O

IUPAC name: (4S,4aR,5S,5aR,6S,12aR)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide

ChEBI definition: A zwitterion obtained by transfer of a proton from the 2-hydroxy group to the adjacent tertiary amino group of oxytetracycline; major species at pH 7.3.

Also known as: Berkmycen, Chemocycline, E703, Galenomycin, Hi-tet, Imperacin, Microtet, Nitox, NSC-757262, NSC-9169, Oxitetraciclina, Oxymycin

Parent form; salt/anhydrous children: CHEMBL1607480, CHEMBL1892210, CHEMBL3989568

Patent coverage: 17,436 distinct patent families (52,933 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Lysine-specific demethylase 4E, Ubiquitin carboxyl-terminal hydrolase 2, Fructose-bisphosphate aldolase, ATP-dependent DNA helicase Q1, 4’-phosphopantetheinyl transferase ffp, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Thyroid hormone receptor beta, Beta-lactamase.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 21 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TDP1	6.4	Potency	398.1	nM	CHEMBL_ACT_3937963
POLB	5.55	Potency	2818	nM	CHEMBL_ACT_4886731
MEN1	5.45	Potency	3548	nM	CHEMBL_ACT_3630882
A8B2U2	5.35	Potency	4456	nM	CHEMBL_ACT_4612026
MAPT	5.2	Potency	6310	nM	CHEMBL_ACT_4023248
HIF1A	5.1	Potency	7943	nM	CHEMBL_ACT_4131681
HIF1A	5.1	Potency	7943	nM	CHEMBL_ACT_4519204

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
eye infectious disorder	4	MONDO:0043885	EFO:1001888
acne	3	MONDO:0011438	EFO:0003894
osteomyelitis	0	MONDO:0005246	EFO:0003102

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03892330	PHASE4	NOT_YET_RECRUITING	Combination Therapy of Anthracyclines for Children With Nephroblastoma
NCT01032499	PHASE3	UNKNOWN	Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).